PV Bulletin
Therapeutic Goods Administration (TGA)Australia

New e-Learning Modules for GCP Inspection Program by TGA

The Therapeutic Goods Administration (TGA) has launched interactive e-learning modules designed to clarify regulatory obligations related to Good Clinical Practice (GCP) inspections in Australia.

PV Impact Brief

Urgency: HighConfidence: high
Relevant for
Regulatory Intelligence LeadPV Quality LeadQPPV
Processes impacted
Inspection ReadinessCountry Compliance
Action needed

Stakeholders are encouraged to utilize the provided e-learning modules to improve their inspection readiness and compliance with GCP standards in Australia.

Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Notice
Policy status
new
Publication date
2026-07-08
Policy change
The TGA has launched new interactive e-learning modules designed to help stakeholders understand their regulatory obligations, including a specific module on the TGA's Good Clinical Practice (GCP) Inspection Program. The module explains the purpose of the inspection program and what sponsors and investigators should expect during an inspection.

Key changes

Launch of the 'Getting started: TGA's Good Clinical Practice (GCP) Inspection Program' module; provides practical examples and context for compliance with GCP standards in Australia.

Affected workflows

Inspection ReadinessCountry Compliance

Responsible groups

Clinical OperationsQuality AssuranceRegulatory Affairs

PV impact

Sponsors and clinical trial teams can use this new official resource to improve inspection readiness for GCP audits. The guidance clarifies the TGA's approach to inspecting safety reporting and trial oversight, which is essential for compliance with clinical trial safety obligations.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jul 8, 2026

Full briefing

What changed

The TGA introduced new e-learning modules specifically detailing the Good Clinical Practice (GCP) Inspection Program and the expectations for sponsors and investigators during inspections.

Why it matters

These educational resources aim to enhance the understanding of GCP compliance, which is critical for ensuring safety in clinical trials and maintaining regulatory standards.

Practical implication

Stakeholders are encouraged to utilize the provided e-learning modules to improve their inspection readiness and compliance with GCP standards in Australia.

#Safety Signals#Notice#new#Therapeutic Goods Administration (TGA)#reporting_requirement#policy-change#firecrawl-policy-agent

Related updates for your role

publicTherapeutic Goods Administration (TGA) · Australia · Updated Jul 7, 2026

Industry Standards for Medicinal Cannabis Vaping Devices - TGA Guidance

Urgency: High

Manufacturers must generate and maintain scientific, engineering, and clinical evidence demonstrating that their devices meet the Essential Principles for Safety and Performance.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicHealth Sciences Authority (HSA) Singapore · Singapore · Updated Jun 30, 2026

Extension of e-labelling to P and GSL medicines

Urgency: High

Manufacturers must adjust labeling workflows to incorporate e-labelling mechanisms, such as QR codes, for P and GSL medicines by the stipulated date.

LabelingRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead, QPPV
verifiedRegulatory action: Regulatory Update / Notice
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 1, 2026

Mandatory Registration for Medical Devices in Switzerland Starting 1 July 2026

Urgency: High

Manufacturers must implement processes for device registration in swissdamed before placing devices on the market, with immediate attention needed for vigilance-reportable incidents.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicHealth Sciences Authority (HSA) · Singapore · Updated Jul 1, 2026

Proposed Regulation for Complementary Health Products in Singapore

Urgency: High

Suppliers must implement new protocols for safety reporting and record-keeping as per the proposed framework.

Country ComplianceSignal ManagementRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead, QPPV
verifiedRegulatory action: Consultation
Read impact briefarrow_forward